Skip to main content
    B

    Bioceres Crop Solutions Corp (BIOX)

    Official site

    BASIC MATERIALS • AGRICULTURAL INPUTS • NASDAQ

    $0.20
    -0.01 (-4.90%)

    Market Cap: $13.40M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Bioceres Crop Solutions Corp (BIOX) Earnings: Report Dates and Results

    Updated Nov 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Bioceres Crop Solutions reported EPS of -$0.16. It beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    15%(4/27)
    Avg Surprise
    -216.36%

    Next Report

    BIOX's next report is not on the earnings calendar yet.

    BIOX Earnings Call

    The latest BIOX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 27 quarters below that had an estimate, BIOX beat 4 and missed 23. The widest gap in the table came in the quarter ended Mar 31, 2022, when EPS landed 900.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.16N/AN/AN/AN/AN/AN/AN/ANov 11, 2026N/A
    Jun 30, 2026-$0.50-$0.06N/A-733.33%MissN/AN/AN/ASep 14, 2026$57.00M
    Mar 31, 2026-$0.14-$0.05-$0.05 - -$0.05-180.00%MissN/A10 up, 1 downMay 11, 2026$38.20M
    Dec 31, 2025-$0.08$0.07$0.07 - $0.07-208.46%Miss-936.8%10 up, 1 downMar 13, 2026$73.67M
    Sep 30, 2025-$0.12$0.03N/A-494.33%MissN/A30 up, 1 downNov 12, 2025$77.44M
    Jun 30, 2025-$0.70$0.10$0.04 - $0.15-800.00%MissN/A20 up, 1 downSep 9, 2025$74.40M
    Mar 31, 2025-$0.02-$0.10-$0.15 - -$0.05+80.00%Beat-114.3%20 up, 1 downMay 21, 2025$59.60M
    Dec 31, 2024$0.01$0.09$0.01 - $0.14-89.44%Miss-52.5%30 up, 1 downFeb 11, 2025$98.88M
    Sep 30, 2024-$0.09-$0.01-$0.14 - $0.10-800.00%MissN/A40 up, 1 downNov 11, 2024$92.62M
    Jun 30, 2024-$0.03$0.24$0.19 - $0.36-112.50%MissN/A50 up, 0 downSep 9, 2024$124.31M
    Mar 31, 2024$0.14$0.17$0.14 - $0.18-17.65%Miss-68.9%40 up, 0 downMay 13, 2024$84.00M
    Dec 31, 2023$0.02$0.09$0.02 - $0.16-77.78%MissN/A50 up, 0 downFeb 8, 2024$140.30M
    Sep 30, 2023-$0.07$0.04$0.03 - $0.10-275.00%Miss-800.0%40 up, 0 downNov 13, 2023$116.18M
    Jun 30, 2023-$0.06$0.05-$0.01 - $0.14-220.00%MissN/A50 up, 0 downSep 11, 2023$105.07M
    Mar 31, 2023$0.45-$0.04-$0.09 - $0.03N/AN/AN/A50 up, 0 downMay 10, 2023$92.98M
    Dec 31, 2022-$0.14$0.14-$0.04 - $0.24-200.00%Miss-275.0%40 up, 0 downFeb 8, 2023$94.55M
    Sep 30, 2022$0.01$0.05$0.01 - $0.09-80.00%Miss-50.0%50 up, 0 downNov 29, 2022$126.84M
    Jun 30, 2022-$0.08$0.16-$0.09 - $0.33-150.00%Miss-500.0%30 up, 0 downSep 8, 2022$101.56M
    Mar 31, 2022-$0.16$0.02N/A-900.00%MissN/A40 up, 0 downMay 27, 2022$68.23M
    Dec 31, 2021$0.08$0.22-$0.38 - $0.27-63.64%Miss+300.0%4N/AFeb 25, 2022$92.31M
    Sep 30, 2021$0.02$0.10$0.01 - $0.15-80.00%MissN/A4N/ANov 30, 2021$66.35M
    Jun 30, 2021$0.02$0.27N/A-92.59%Miss-60.0%N/AN/ASep 9, 2021$81.05M
    Mar 31, 2021-$0.03-$0.05-$0.07 - -$0.03+40.00%BeatN/A2N/AMay 28, 2021$35.54M
    Dec 31, 2020$0.02$0.36$0.36 - $0.36-94.44%Miss-93.5%1N/AFeb 26, 2021$48.00M
    Sep 30, 2020-$0.17$0.08$0.08 - $0.08-312.50%MissN/A1N/ANov 30, 2020$42.11M
    Jun 30, 2020$0.05$0.22$0.20 - $0.23-77.27%MissN/A2N/ASep 28, 2020$48.13M
    Mar 31, 2020-$0.09-$0.11-$0.14 - -$0.09+18.18%BeatN/A2N/AMay 28, 2020$25.72M
    Dec 31, 2019$0.31$0.33$0.31 - $0.35-6.06%MissN/A2N/AMar 6, 2020$62.27M
    Sep 30, 2019-$0.03-$0.20N/A+85.00%BeatN/AN/AN/ADec 2, 2019$36.23M
    Jun 30, 2019-$0.04N/AN/AN/AN/AN/AN/AN/ASep 13, 2019$36.23M
    Mar 31, 2019-$0.72N/AN/AN/AN/AN/AN/AN/AMar 31, 2019$18.68M
    Dec 31, 2018-$0.11N/AN/AN/AN/AN/AN/AN/AJan 30, 2019$62.45M
    Sep 30, 2018-$0.06N/AN/AN/AN/AN/AN/AN/AOct 30, 2018$29.61M
    Jun 30, 2018-$0.11N/AN/AN/AN/AN/AN/AN/AJul 30, 2018$31.61M
    Mar 31, 2018-$0.06N/AN/AN/AN/AN/AN/AN/AApr 29, 2018$20.90M
    Last 35 quarters

    Annual EPS

    EPS for the fiscal year ended Jun 30, 2026 was -$0.84, after -$0.80 the year before. It was -$0.17 for the year ended Jun 30, 2018, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Jun 30, 2026-$0.84N/A
    Jun 30, 2025-$0.80-1434.2%
    Jun 30, 2024$0.06-76.9%
    Jun 30, 2023$0.26N/A
    Jun 30, 2022-$0.14N/A
    Jun 30, 2021-$0.16-166.7%
    Jun 30, 2020$0.24N/A
    Jun 30, 2019-$0.93N/A
    Jun 30, 2018-$0.17N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,500 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,4966
    2026Q1Mar 31, 20262,0474
    2025Q4Dec 31, 20253,8157
    2025Q3Sep 30, 20256,97510
    2025Q2Jun 30, 20257,5879
    2025Q1Mar 31, 20255,5838
    2024Q4Dec 31, 20247,5339
    2024Q3Sep 30, 20246,6898

    2026Q3 Earnings Call

    Opening remarks

    Paula Savanti Head of Investor Relations Thank you, and good morning, everyone. Welcome to Bioceres Crop Solutions Third Fiscal Quarter 2026 Earnings Conference Call. Our prepared remarks today will be led by our Chief Executive Officer, Federico Trucco; our General Counsel, Jose Roque; and our Chief Financial Officer, Ezequiel Simmermacher. All of them will be available for the Q&A session following the presentation. During this call, we will be making forward-looking statements. These statements are based on current expectations and assumptions that are subject to various risks and uncertainties. I refer you to the forward-looking statements section of the earnings release and presentation as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. In today's presentation, we will be making references to certain non-GAAP financial measures. Reconciliations of the non-GAAP measures can be found in our earnings press release. This conference call is being webcast, and the link is available at our Investor Relations website. It is now my pleasure to turn the call over to Federico.

    Federico Trucco Chief Executive Officer Thanks, Paula, and good morning to everyone. Thanks for joining us today. Please turn to Slide 3 for today's key business and financial highlights. This quarter reflects a period of transition and operational refocusing for the company, while it is historically our weakest quarter from a baseline business perspective. Total revenues and gross profits showed a decline compared to the same quarter last year, which was partially offset by an improvement in operational expenses. Net loss was $10 million, primarily reflecting lower gross profit as well as increased financial expenses, all of which will be described in greater detail later in the presentation. Also, in the last 3 years, we have booked profits from IP rights and other commercial arrangements in this quarter, which helped us offset baseline operating losses. Although we continue to explore strategic arrangements with our partners on a regular basis and see these as a recurrent source of profitability, this year, the timing of profit-generating arrangements did not coincide with the initial months of the calendar year. As I have stated in my message to shareholders of March 16, we recognize the significance of the events surrounding Pro Farm and the uncertainty generated by the ongoing litigation process. Jose Roque, our General Counsel, will now provide an update of the ongoing litigation. Please turn to Slide 4.

    Jose Roque General Counsel Thank you, Federico, and good morning to everyone on the call. As previously disclosed, in November 2025, four holders of secured notes issued under our note purchase agreements dated August 2022 filed a lawsuit in New York against the company and certain guarantor affiliates.

    Frequently Asked Questions About BIOX

    How often does BIOX beat earnings estimates?

    Bioceres Crop Solutions beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate, with an average surprise of -403.20%.